Office located in Fremont, CA
Platform personalising cancer testing
Job no longer available
Platform personalising cancer testing
201-500 employees
Job no longer available
Office located in Fremont, CA
201-500 employees
To transform the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response.
Personalis is developing biopharmaceuticals for cancer immunotherapies, enabling the next generation of precision cancer therapies and diagnostics.
A leader in advanced cancer genomics, Personalis is evolving its understanding of cancer through the 'Personalis NeXT Platform®'. This provides biopharmaceutical customers and clinicians with information on approximately 20,000 human genes and the immune systems all from a single sample.
Through multiple funding rounds, including investors such as Stanford University, Lightspeed Venture Partners, Abingworth, and Merck, Personalis has obtained capital to grow its products and advance its knowledge in developing the next generation of cancer diagnostics.

Steph
Company Specialist at Welcome to the Jungle
-13% employee growth in 12 months
Jan 2015
$33m
SERIES C
Oct 2013
$22m
SERIES B
Fremont, CA
Atul Butte
(Founder & Scientific Advisor)Previously worked at Stanford University, School of Medicine as a Professor of Pediatrics and as a Chief, Division of Systems Medicine in the Department of Pediatrics.
Christopher (Chris) Hall
(President & CEO)Joined the company in 2022 as SVP and Head of Diagnostic Business, becoming CEO in 2023. Formerly CEO at Naring Health, President and COO at Veracyte, and SVP at Celera.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 2 more jobs at Personalis
